Publications

This was an exploratory post hoc analysis of pooled data, from over 2000 patients in three Phase 3 studies of tofacitinib, which demonstrates an association between tofacitinib treatment and significantly greater improvements in fatigue, sleep, and health-related quality of life (HRQoL), compared with placebo.

Affecting a large majority of patients with RA, fatigue is a common symptom of the disease and is detrimental to HRQoL. However, the clinical significance of this overwhelming, unpredictable, and severely disabling symptom associated with sleep disturbance, pain, anxiety, and depression, may be overlooked.

To this end, Bartlett, et al. undertook this post hoc analysis to evaluate the impact of tofacitinib on fatigue, sleep, and HRQoL, and explored associations between fatigue, related patient-reported outcomes and disease activity in patients with RA.